SC
ADCT icon

Steven Cohen’s ADC Therapeutics ADCT Stock Holding History

Steven Cohen’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.2K Hold
26,400
– – ﹤0.01% 3849
2026
Q1 		$99K Buy
+26,400
New +$104K ﹤0.01% 3612

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's ADCT Position: Q2 2026 in Review

Steven Cohen increased its ADC Therapeutics (ADCT) stake by 7.9% in Q2 2026, buying an estimated $779K and bringing the position to 3,649,144 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1935.

Steven Cohen first reported a position in ADCT in Q4 2022 and has held it in 6 quarters since. The position peaked at $32.5M in Q3 2025. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Steven Cohen held 3,649,144 shares of ADC Therapeutics worth $3.9M as of Q2 2026.
  • Steven Cohen bought 267,015 ADC Therapeutics shares in Q2 2026, an estimated $779K.
  • ADC Therapeutics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #1935 holding.
  • Steven Cohen first reported a position in ADC Therapeutics in Q4 2022 and has held it in 6 quarters since.
  • Steven Cohen's ADC Therapeutics position peaked at $32.5M in Q3 2025.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.